Novartis cut its mid-term sales growth target as blockbuster patents expire
Peak sales guidance is higher for Kesimpta, Scemblix and Leqvio, and Novartis said its core margin is on track to return to 40% or higher by 2029
We haven't written up this one. Quartz has the full story — the link below goes straight to it.